Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia Akebia to assume responsibility for regulatory review processes previously led by Otsuka CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a…

Click here to view original post